Molecular biomarkers and ablative therapies for Barrett's esophagus

Jacob Chisholm, George Mayne, Damian Hussey, David Watson

    Research output: Contribution to journalReview articlepeer-review

    4 Citations (Scopus)


    Barrett's esophagus is the major risk factor for esophageal adenocarcinoma. Endoscopic interventions that ablate Barrett's esophagus mucosa lead to replacement with a new squamous (neosquamous) mucosa, but it can be difficult to achieve complete ablation. Knowing whether cancer is less likely to develop in neosquamous mucosa or residual Barrett's esophagus after ablation is critical for determining the efficacy of treatment. This issue can be informed by assessing biomarkers that are associated with an increased risk of progression to adenocarcinoma. Although there are few postablation biomarker studies, evidence suggests that neosquamous mucosa may have a reduced risk of adenocarcinoma in patients who have been treated for dysplasia or cancer, but some patients who do not have complete eradication of nondysplastic Barrett's esophagus may still be at risk. Biomarkers could be used to optimize endoscopic surveillance strategies following ablation, but this needs to be assessed by clinical studies and economic modeling.

    Original languageEnglish
    Pages (from-to)567-581
    Number of pages15
    JournalExpert Review of Gastroenterolgy and Hepatology
    Issue number5
    Publication statusPublished - Sept 2012


    • ablation
    • Barrett's esophagus
    • biomarkers
    • esophageal adenocarcinoma


    Dive into the research topics of 'Molecular biomarkers and ablative therapies for Barrett's esophagus'. Together they form a unique fingerprint.

    Cite this